Education
About Us
Working with TipRanks
Follow Us
LivaNova PLC (LIVN)
NASDAQ:LIVN
LIVN Stock Chart & Stats
$61.43
$0.70(1.49%)
At close: 4:00 PM EST
$61.43
$0.70(1.49%)
Day’s Range― - ―
52-Week Range$32.48 - $71.92
Previous CloseN/A
Volume66.13K
Average Volume (3M)900.27K
Market Cap
$3.36B
Enterprise Value$3.25B
Total Cash (Recent Filing)$635.60M
Total Debt (Recent Filing)$473.30M
Price to Earnings (P/E)―
Beta1.02
Next Earnings
May 06, 2026EPS Estimate
0.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.86
Shares Outstanding54,689,877
10 Day Avg. Volume970,613
30 Day Avg. Volume900,271
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.79
Price to Sales (P/S)2.42
P/FCF Ratio19.36
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue2.34
Enterprise Value/Gross Profit3.44
Enterprise Value/Ebitda-26.97
Forecast
1Y Price Target
$80.13Price Target Upside30.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)4.21
Revenue Forecast (FY)$1.49B
Bulls Say, Bears Say
Bulls Say
Guidance And Supply Upside PotentialPrudent initial guidance and conservative component supply assumptions create upside potential if product pricing, volumes, or supply conditions improve.
Neuromodulation GrowthStronger neuromodulation growth supports future revenue expansion and could drive share gains within the device market.
Regulatory And Reimbursement ProgressImproved epilepsy reimbursement and progressing regulatory approval for an obstructive sleep apnea device could open new revenue channels and expand the addressable market.
Bears Say
Cardiopulmonary SlowdownSlowing cardiopulmonary business growth could weigh on overall momentum and pressure near-term revenue expectations.
Execution And Margin RiskExecution risk around commercializing new platforms and converting growth into margin improvement may limit near-term profit expansion if adoption or cost leverage lags.
Legal OverhangOngoing Italian litigation remains an overhang that could keep valuation constrained until a favorable resolution is reached.
LivaNova News
LIVN FAQ
What was LivaNova PLC’s price range in the past 12 months?
LivaNova PLC lowest stock price was $32.48 and its highest was $71.92 in the past 12 months.
What is LivaNova PLC’s market cap?
LivaNova PLC’s market cap is $3.36B.
When is LivaNova PLC’s upcoming earnings report date?
LivaNova PLC’s upcoming earnings report date is May 06, 2026 which is in 49 days.
How were LivaNova PLC’s earnings last quarter?
LivaNova PLC released its earnings results on Feb 25, 2026. The company reported $0.86 earnings per share for the quarter, beating the consensus estimate of $0.815 by $0.045.
Is LivaNova PLC overvalued?
According to Wall Street analysts LivaNova PLC’s price is currently Undervalued.
Does LivaNova PLC pay dividends?
LivaNova PLC does not currently pay dividends.
What is LivaNova PLC’s EPS estimate?
LivaNova PLC’s EPS estimate is 0.9.
How many shares outstanding does LivaNova PLC have?
LivaNova PLC has 54,689,877 shares outstanding.
What happened to LivaNova PLC’s price movement after its last earnings report?
LivaNova PLC reported an EPS of $0.86 in its last earnings report, beating expectations of $0.815. Following the earnings report the stock price went up 1.796%.
Which hedge fund is a major shareholder of LivaNova PLC?
Currently, no hedge funds are holding shares in LIVN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
LivaNova Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$80.13 (30.44% Upside)
$80.13 (30.44% Upside)
Blogger Sentiment
Bullish
LIVN Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 452.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 4.8%
Last 30 Days ▲ 10.8%
Last 30 Days ▲ 10.8%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
56.54%
12-Months-Change
Fundamentals
Return on Equity
-21.49%
Trailing 12-Months
Asset Growth
3.98%
Trailing 12-Months
Company Description
LivaNova PLC
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products, such as cardiopulmonary and respiratory support solutions. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
LIVN Company Deck
LIVN Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated solid commercial and financial momentum: double-digit growth in core businesses, margin expansion, stronger cash and materially lower debt, meaningful Medicare reimbursement improvements for epilepsy, and multiple clinical/regulatory milestones (FDA digital platform approval, OSPREY data, OSA PMA timeline). Offsetting items include supply constraints for oxygenators, increased R&D and capex for strategic launches, a significant assumed SNIA cash payment in 2026, and conservative near-term guidance reflecting component constraints and tougher comps. Overall, the company appears well-positioned for medium-term growth while prudently managing near-term operational and cash assumptions.View all LIVN earnings summariesLIVN Stock 12 Month Forecast
Average Price Target
$80.13
▲(30.44% Upside)
Technical Analysis
Artivion
―
Integer Holdings
―
Ufp Technologies
―
Inspire Medical Systems
―
TransMedics Group
―
Ownership Overview
0.28% Insiders
29.63% Mutual Funds
29.49% Other Institutional Investors
18.61% Public Companies and
Individual Investors